Cargando…
Intermediate-High Risk Pulmonary Embolism: The Use of Riociguat and Inferior Vena Cava Filter in a Situation of Recurrent Embolism following Insufficient Anticoagulation and Fibrinolytic Therapy
Pulmonary embolism (PE) is associated with serious morbidity and mortality. In this case report, we describe a hemodynamically stable patient with submassive PE and a large thrombus in the inferior vena cava (IVC) protruding into the right atrium (RA), complicated by severe respiratory failure, elev...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7603563/ https://www.ncbi.nlm.nih.gov/pubmed/33149952 http://dx.doi.org/10.1155/2020/4219616 |
_version_ | 1783603950622081024 |
---|---|
author | Vo, Anh Khoi Reikvam, Håkon Midtbø, Helga Wirsching, Jan Ludvig Bruserud, Øyvind Wendelbo, Øystein |
author_facet | Vo, Anh Khoi Reikvam, Håkon Midtbø, Helga Wirsching, Jan Ludvig Bruserud, Øyvind Wendelbo, Øystein |
author_sort | Vo, Anh Khoi |
collection | PubMed |
description | Pulmonary embolism (PE) is associated with serious morbidity and mortality. In this case report, we describe a hemodynamically stable patient with submassive PE and a large thrombus in the inferior vena cava (IVC) protruding into the right atrium (RA), complicated by severe respiratory failure, elevated troponin T (TnT), and right ventricular (RV) dysfunction. The patient was stratified as intermediate-high risk of early death. Important issues regarding the initial choice of anticoagulation, rescue thrombolytic therapy, and benefits of adding riociguat to stimulate the nitric oxide-soluble guanylate cyclase-cyclic guanosine monophosphate (NO-sGC-cGMP) pathway to improve the RV function are discussed. Finally, we address appropriate timing and the use of IVC filter in a situation of recurrent PE following anticoagulation and fibrinolytic therapy. |
format | Online Article Text |
id | pubmed-7603563 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-76035632020-11-03 Intermediate-High Risk Pulmonary Embolism: The Use of Riociguat and Inferior Vena Cava Filter in a Situation of Recurrent Embolism following Insufficient Anticoagulation and Fibrinolytic Therapy Vo, Anh Khoi Reikvam, Håkon Midtbø, Helga Wirsching, Jan Ludvig Bruserud, Øyvind Wendelbo, Øystein Case Rep Anesthesiol Case Report Pulmonary embolism (PE) is associated with serious morbidity and mortality. In this case report, we describe a hemodynamically stable patient with submassive PE and a large thrombus in the inferior vena cava (IVC) protruding into the right atrium (RA), complicated by severe respiratory failure, elevated troponin T (TnT), and right ventricular (RV) dysfunction. The patient was stratified as intermediate-high risk of early death. Important issues regarding the initial choice of anticoagulation, rescue thrombolytic therapy, and benefits of adding riociguat to stimulate the nitric oxide-soluble guanylate cyclase-cyclic guanosine monophosphate (NO-sGC-cGMP) pathway to improve the RV function are discussed. Finally, we address appropriate timing and the use of IVC filter in a situation of recurrent PE following anticoagulation and fibrinolytic therapy. Hindawi 2020-10-15 /pmc/articles/PMC7603563/ /pubmed/33149952 http://dx.doi.org/10.1155/2020/4219616 Text en Copyright © 2020 Anh Khoi Vo et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Vo, Anh Khoi Reikvam, Håkon Midtbø, Helga Wirsching, Jan Ludvig Bruserud, Øyvind Wendelbo, Øystein Intermediate-High Risk Pulmonary Embolism: The Use of Riociguat and Inferior Vena Cava Filter in a Situation of Recurrent Embolism following Insufficient Anticoagulation and Fibrinolytic Therapy |
title | Intermediate-High Risk Pulmonary Embolism: The Use of Riociguat and Inferior Vena Cava Filter in a Situation of Recurrent Embolism following Insufficient Anticoagulation and Fibrinolytic Therapy |
title_full | Intermediate-High Risk Pulmonary Embolism: The Use of Riociguat and Inferior Vena Cava Filter in a Situation of Recurrent Embolism following Insufficient Anticoagulation and Fibrinolytic Therapy |
title_fullStr | Intermediate-High Risk Pulmonary Embolism: The Use of Riociguat and Inferior Vena Cava Filter in a Situation of Recurrent Embolism following Insufficient Anticoagulation and Fibrinolytic Therapy |
title_full_unstemmed | Intermediate-High Risk Pulmonary Embolism: The Use of Riociguat and Inferior Vena Cava Filter in a Situation of Recurrent Embolism following Insufficient Anticoagulation and Fibrinolytic Therapy |
title_short | Intermediate-High Risk Pulmonary Embolism: The Use of Riociguat and Inferior Vena Cava Filter in a Situation of Recurrent Embolism following Insufficient Anticoagulation and Fibrinolytic Therapy |
title_sort | intermediate-high risk pulmonary embolism: the use of riociguat and inferior vena cava filter in a situation of recurrent embolism following insufficient anticoagulation and fibrinolytic therapy |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7603563/ https://www.ncbi.nlm.nih.gov/pubmed/33149952 http://dx.doi.org/10.1155/2020/4219616 |
work_keys_str_mv | AT voanhkhoi intermediatehighriskpulmonaryembolismtheuseofriociguatandinferiorvenacavafilterinasituationofrecurrentembolismfollowinginsufficientanticoagulationandfibrinolytictherapy AT reikvamhakon intermediatehighriskpulmonaryembolismtheuseofriociguatandinferiorvenacavafilterinasituationofrecurrentembolismfollowinginsufficientanticoagulationandfibrinolytictherapy AT midtbøhelga intermediatehighriskpulmonaryembolismtheuseofriociguatandinferiorvenacavafilterinasituationofrecurrentembolismfollowinginsufficientanticoagulationandfibrinolytictherapy AT wirschingjanludvig intermediatehighriskpulmonaryembolismtheuseofriociguatandinferiorvenacavafilterinasituationofrecurrentembolismfollowinginsufficientanticoagulationandfibrinolytictherapy AT bruserudøyvind intermediatehighriskpulmonaryembolismtheuseofriociguatandinferiorvenacavafilterinasituationofrecurrentembolismfollowinginsufficientanticoagulationandfibrinolytictherapy AT wendelboøystein intermediatehighriskpulmonaryembolismtheuseofriociguatandinferiorvenacavafilterinasituationofrecurrentembolismfollowinginsufficientanticoagulationandfibrinolytictherapy |